SCHEMBL3023124

SCHEMBL3023124

Cc1cc(NS(C)(=O)=O)cc2c1C(c1ccc(F)cc1)=C(F)C(C)(C)O2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 6/20 0.47
TNIK Q9UKE5 1/20 0.39
BRD4 O60885 2/20 0.39
PTGS2 P35354 3/20 0.34
MAP2K4 P45985 1/20 0.34
ABL1 P00519 1/20 0.34
KIT P10721 2/20 0.34
DYRK1A Q13627 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3026781 0.89 NR3C2 (0.46) NR3C2TNIKBRD4PTGS2MAP2K4
SCHEMBL12081744 0.88 NR3C2 (0.47) NR3C2BRD4PTGS2MAP2K4
SCHEMBL3016915 0.86 NR3C2 (0.46) NR3C2TNIKBRD4PTGS2MAP2K4
SCHEMBL14670427 0.83 BRD4 (0.35) NR3C2BRD4MEN1KMT2A
SCHEMBL3027006 0.81 NR3C2 (0.55) NR3C2TNIKBRD4PTGS2MAP2K4
SCHEMBL13234996 0.81 BRD4 (0.31) NR3C2BRD4
SCHEMBL3017143 0.80 NR3C2 (0.43) NR3C2TNIKBRD4PTGS2MAP2K4
SCHEMBL3019474 0.79 NR3C2 (0.42) NR3C2TNIKBRD4PTGS2MAP2K4
SCHEMBL3018663 0.76 NR3C2 (0.47) NR3C2BRD4PTGS2KIT
SCHEMBL3031327 0.76 NR3C2 (0.54) NR3C2TNIKBRD4MAP2K4KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2179994-B1 FUSED BICYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-26 EP disclosed
US-8410166-B2 Fused bicyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-04-02 US disclosed
US-20130029979-A1 FUSED BICYCLIC COMPOUND TAKAHASHI YOICHI (JP) 2013-01-31 US disclosed
US-8258131-B2 Fused bicyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-09-04 US disclosed
US-8258131-B2 Fused bicyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-09-04 US disclosed
US-8258131-B2 Fused bicyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-09-04 US disclosed
US-20100204218-A1 FUSED BICYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-08-12 US disclosed
US-20100204218-A1 FUSED BICYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-08-12 US disclosed
EP-2179994-A1 FUSED BICYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029979-A1 FUSED BICYCLIC COMPOUND NR3C2, NR3C1, MC2R NR3C2 1/4885TNIK 4811/4885BRD4 112/4885
US-20100204218-A1 FUSED BICYCLIC COMPOUND NR3C2, NR3C1, MC2R NR3C2 1/4885TNIK 4770/4885BRD4 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.